Darzalex (daratumumab) 400 mg/20 mL concentrate for solution for infusion, 1 vial (Janssen) Multiple myeloma treatment. Targeted cancer therapy. Delivery of medications from Europe within 4-5 days, storage conditions observed, payment upon receipt. +380996042415 Viber, WhatsApp.

Darzalex^® acknowledge:

• The combination of bortezomib, melphalan and prednisone for the treatment of adult patients with previously diagnosed multiple myeloma who are not candidates for autologous transplantation of stovburov cells;
• as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, the upfront therapy of which included a proteasome inhibitor and an immunomodulatory drug and in whom there was progression illness during the course of continued therapy;
• in stock of combination therapy with lenalidomide and dexamethasone, or bortezomib and dexamethasone for the treatment of adult patients with with multiple myeloma, who took at least one line of therapy.
•